217 related articles for article (PubMed ID: 19383215)
1. Dose-finding study of fluoxetine and venlafaxine for the treatment of self-injurious and stereotypic behavior in rhesus macaques (Macaca mulatta).
Fontenot MB; Musso MW; McFatter RM; Anderson GM
J Am Assoc Lab Anim Sci; 2009 Mar; 48(2):176-84. PubMed ID: 19383215
[TBL] [Abstract][Full Text] [Related]
2. The effects of fluoxetine and buspirone on self-injurious and stereotypic behavior in adult male rhesus macaques.
Fontenot MB; Padgett EE; Dupuy AM; Lynch CR; De Petrillo PB; Higley JD
Comp Med; 2005 Feb; 55(1):67-74. PubMed ID: 15766212
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.
Sawyer EK; Howell LL
Pharmacology; 2011; 88(1-2):44-9. PubMed ID: 21757974
[TBL] [Abstract][Full Text] [Related]
4. Effects of outdoor housing on self-injurious and stereotypic behavior in adult male rhesus macaques (Macaca mulatta).
Fontenot MB; Wilkes MN; Lynch CS
J Am Assoc Lab Anim Sci; 2006 Sep; 45(5):35-43. PubMed ID: 16995645
[TBL] [Abstract][Full Text] [Related]
5. Self-injurious behavior is decreased by cyproterone acetate in adult male rhesus (Macaca mulatta).
Eaton GG; Worlein JM; Kelley ST; Vijayaraghavan S; Hess DL; Axthelm MK; Bethea CL
Horm Behav; 1999 Apr; 35(2):195-203. PubMed ID: 10202127
[TBL] [Abstract][Full Text] [Related]
6. Ancestral Fluoxetine Exposure Sensitizes Zebrafish to Venlafaxine-Induced Reductions in Cortisol and Spawning.
Vera-Chang MN; Moon TW; Trudeau VL
Endocrinology; 2019 Sep; 160(9):2137-2142. PubMed ID: 31305910
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 fatty acid deficiency does not alter the effects of chronic fluoxetine treatment on central serotonin turnover or behavior in the forced swim test in female rats.
McNamara RK; Able JA; Liu Y; Jandacek R; Rider T; Tso P; Lipton JW
Pharmacol Biochem Behav; 2013 Dec; 114-115():1-8. PubMed ID: 24090922
[TBL] [Abstract][Full Text] [Related]
8. Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy.
Wikell C; Kugelberg FC; Hjorth S; Apelqvist G; Bengtsson F
Clin Neuropharmacol; 2001; 24(6):324-33. PubMed ID: 11801807
[TBL] [Abstract][Full Text] [Related]
9. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
10. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
Kennedy SH; McCann SM; Masellis M; McIntyre RS; Raskin J; McKay G; Baker GB
J Clin Psychiatry; 2002 Mar; 63(3):181-6. PubMed ID: 11926715
[TBL] [Abstract][Full Text] [Related]
11. Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.
Golub MS; Hogrefe CE
Psychopharmacology (Berl); 2014 Oct; 231(20):4041-7. PubMed ID: 24700388
[TBL] [Abstract][Full Text] [Related]
12. Effect of tryptophan treatment on self-biting and central nervous system serotonin metabolism in rhesus monkeys (Macaca mulatta).
Weld KP; Mench JA; Woodward RA; Bolesta MS; Suomi SJ; Higley JD
Neuropsychopharmacology; 1998 Oct; 19(4):314-21. PubMed ID: 9718594
[TBL] [Abstract][Full Text] [Related]
13. Differential physiological effects of a low dose and high doses of venlafaxine in major depression.
Debonnel G; Saint-André E; Hébert C; de Montigny C; Lavoie N; Blier P
Int J Neuropsychopharmacol; 2007 Feb; 10(1):51-61. PubMed ID: 16690006
[TBL] [Abstract][Full Text] [Related]
14. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
Gibbons RD; Hur K; Brown CH; Davis JM; Mann JJ
Arch Gen Psychiatry; 2012 Jun; 69(6):572-9. PubMed ID: 22393205
[TBL] [Abstract][Full Text] [Related]
15. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine and norfluoxetine.
Mattes JA
Am J Psychiatry; 1998 Nov; 155(11):1637. PubMed ID: 9812147
[No Abstract] [Full Text] [Related]
17. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs.
Epperson CN; Jatlow PI; Czarkowski K; Anderson GM
Pediatrics; 2003 Nov; 112(5):e425. PubMed ID: 14595087
[TBL] [Abstract][Full Text] [Related]
18. Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.
Wikell C; Bergqvist PB; Hjorth S; Apelqvist G; Björk H; Bengtsson F
Clin Neuropharmacol; 1998; 21(5):296-306. PubMed ID: 9789710
[TBL] [Abstract][Full Text] [Related]
19. Hidden in the sand: Alteration of burying behaviour in shore crabs and cuttlefish by antidepressant exposure.
Chabenat A; Bellanger C; Jozet-Alves C; Knigge T
Ecotoxicol Environ Saf; 2019 Dec; 186():109738. PubMed ID: 31610357
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive insight into the transformation pathways and products of fluoxetine and venlafaxine in wastewater based on molecular networking nontarget screening.
Wu G; Wu T; Chen Y; He X; Liu P; Wang D; Geng J; Zhang XX
Sci Total Environ; 2024 Jan; 907():167727. PubMed ID: 37864996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
